Streetbeat News

Products Services

EFTR

eFFECTOR Therapeutics has been granted FDA Fast Track Designation for Zotatifin in combination with Fulvestrant and Abemaciclib for the treatment of ER+/HER2- advanced metastatic breast cancer. This designation could expedite the development and review process for Zotatifin, potentially bringing it to market more quickly if it proves to be safe and effective.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:03 pm

YTRA

Yatra Online has entered into a partnership with Aramco Asia to cater to the travel needs in the region. This collaboration aims to address the increasing demand for travel services in Asia by leveraging Yatra's expertise in travel management and Aramco's presence in the region.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:03 pm

ACRV

Acrivon Therapeutics has announced that the FDA has granted a device designation for its ACR-368 OncoSignature Assay, which is used in a Phase 2 trial to predict patient response to the CHK1/2 inhibitor ACR-368 for ovarian cancer. The assay is part of Acrivon's AP3 platform, which aids in drug design and understanding resistance mechanisms.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:03 pm

ACN

SAP

Accenture (ACN) is partnering with SAP SE to develop a supply chain nerve center aimed at reducing risk, enhancing visibility, and supporting sustainability goals. The collaboration will focus on co-developing new capabilities for SAP's Integrated Business Planning for Supply Chain (SAP IBP) solution, enabling organizations to respond more effectively to changes in supply, demand, and inventory.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:01 pm

CMND

Clearmind Medicine has reported positive outcomes from a pre-clinical trial, suggesting potential effects in improving metabolic parameters such as fat oxidation, weight loss, and reduced appetite.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:00 pm

CMND

SPRC

Clearmind Medicine Inc (NASDAQ:CMND) and SciSparc Ltd (NASDAQ:SPRC) have reported positive preclinical trial results for a combination therapy treating obesity and metabolic disorders. The therapy combines Clearmind's psychedelic MEAI and SciSparc's anti-inflammatory PEA. The trial found optimal dosages that increased metabolic processes and fat burn while reducing appetite and meal sizes without affecting animal viability. Clearmind also announced a 1-for-30 reverse share split effective today.

Portfolio Pulse from Vandana Singh

November 28, 2023 | 1:00 pm

CMND

Clearmind Medicine has announced positive pre-clinical results for its proprietary psychedelic-based treatment aimed at weight loss and metabolic disorders. The company's findings could pave the way for new treatments in the obesity and diabetes markets, which are areas of significant unmet medical need.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:00 pm

BTTX

Better Therapeutics, Inc. (NASDAQ:BTTX) has amended its debt facility with Hercules Capital, Inc. to extend the Interest Only period, redeem debt without penalties, and potentially remove the minimum cash covenant. The amendment also allows for debt-to-equity conversion under certain conditions. Additionally, Better Therapeutics is implementing cost-saving measures, including salary reductions, to improve its financial position by $5M through Q1 2024. These steps are taken to support the commercial launch of its FDA-authorized lead product, AspyreRx, for type 2 diabetes treatment.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:50 pm

WAB

Wabtec Corporation and Marinsa International have signed a contract to supply engines for 10 new hybrid tugboats for the Panama Canal Authority. Wabtec will provide two 8L250MDA marine engines for each tugboat, focusing on maximum availability and low life-cycle cost. Financial terms of the deal were not disclosed.

Portfolio Pulse from Charles Gross

November 28, 2023 | 12:42 pm

AAPL

META

Apple Inc.'s (AAPL) new NameDrop feature, introduced in iOS 17.1 and watchOS 10.1, is being misrepresented by police departments in several states, leading to misinformation about its functionality. Contrary to police claims that devices can share contact information by just being in close proximity, NameDrop actually requires devices to be nearly touching and both unlocked, with a prompt for consent. The incorrect information has spread widely on social media, including on Facebook, owned by Meta Platforms Inc. (META).

Portfolio Pulse from Rounak Jain

November 28, 2023 | 12:41 pm